Dr Fieke Froeling

  • Clinical Senior Lecturer (Clinical Research Garscube)

email: Fieke.Froeling@glasgow.ac.uk

Research Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, Garscube Campus, Glasgow, G61 1QH

Import to contacts

ORCID iDhttps://orcid.org/0000-0002-8653-8164

Research interests

Research groups

  • Cancer Evolution in Time & Space
  • Immunology & Cancer
  • Health Inequalities to Cancer Outcomes

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021
Number of items: 6.

2024

Bryce, A. , Dreyer, S., Dolan, R. , Froeling, F. and Chang, D. (2024) Host phenotypic adversity independently predicts progression to resection in neoadjuvantly-treated pancreatic cancer. 42nd Congress of the European Society of Surgical Oncology, Florence, Italy, 25-27 Oct 2023. (doi: 10.1016/j.ejso.2023.107753)

2023

Chung, T., Garcia, L., Swamynathan, M. M., Froeling, F. E.M. , Trotman, L. C., Tuveson, D. A. and Lyons, S. K. (2023) Internally controlled and dynamic optical measures of functional tumor biology. Analytical Chemistry, 95(13), pp. 5661-5670. (doi: 10.1021/acs.analchem.2c05450) (PMID:36952386) (PMCID:PMC10077328)

2022

Bryce, A. S. , Dreyer, S. B., Froeling, F. E.M. and Chang, D. K. (2022) Exploring the biology of cancer-associated fibroblasts in pancreatic cancer. Cancers, 14(21), 5302. (doi: 10.3390/cancers14215302) (PMID:36358721) (PMCID:PMC9659154)

2021

Casolino, R. et al. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39(23), pp. 2617-2631. (doi: 10.1200/JCO.20.03238) (PMID:34197182) (PMCID:PMC8331063)

Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)

Froeling, F. E.M. , Casolino, R., Pea, A., Biankin, A. V. and Chang, D. K. (2021) Molecular subtyping and precision medicine for pancreatic cancer. Journal of Clinical Medicine, 10(1), 149. (doi: 10.3390/jcm10010149) (PMID:33406790) (PMCID:PMC7794969)

This list was generated on Thu Nov 21 03:12:03 2024 GMT.
Jump to: Articles | Conference or Workshop Item
Number of items: 6.

Articles

Chung, T., Garcia, L., Swamynathan, M. M., Froeling, F. E.M. , Trotman, L. C., Tuveson, D. A. and Lyons, S. K. (2023) Internally controlled and dynamic optical measures of functional tumor biology. Analytical Chemistry, 95(13), pp. 5661-5670. (doi: 10.1021/acs.analchem.2c05450) (PMID:36952386) (PMCID:PMC10077328)

Bryce, A. S. , Dreyer, S. B., Froeling, F. E.M. and Chang, D. K. (2022) Exploring the biology of cancer-associated fibroblasts in pancreatic cancer. Cancers, 14(21), 5302. (doi: 10.3390/cancers14215302) (PMID:36358721) (PMCID:PMC9659154)

Casolino, R. et al. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39(23), pp. 2617-2631. (doi: 10.1200/JCO.20.03238) (PMID:34197182) (PMCID:PMC8331063)

Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)

Froeling, F. E.M. , Casolino, R., Pea, A., Biankin, A. V. and Chang, D. K. (2021) Molecular subtyping and precision medicine for pancreatic cancer. Journal of Clinical Medicine, 10(1), 149. (doi: 10.3390/jcm10010149) (PMID:33406790) (PMCID:PMC7794969)

Conference or Workshop Item

Bryce, A. , Dreyer, S., Dolan, R. , Froeling, F. and Chang, D. (2024) Host phenotypic adversity independently predicts progression to resection in neoadjuvantly-treated pancreatic cancer. 42nd Congress of the European Society of Surgical Oncology, Florence, Italy, 25-27 Oct 2023. (doi: 10.1016/j.ejso.2023.107753)

This list was generated on Thu Nov 21 03:12:03 2024 GMT.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Cancer Inequities SAMBAl: Societal, Ancestry and Molecular Burdens of Analyses
    Cancer Research UK
    2024 - 2025
     
  • Societal, Ancestry, Molecular and Biological Analyses of Inequalities: SAMBAI
    National Cancer Institute
    2024 - 2025
     
  • IPMN Proteomic work
    Universita Degli Studi Di Verona
    2023 - 2025
     
  • Deciphering the mechanisms of progression from intraductal papillary mucinous neoplasms into invasive cancer to inform optimal timing of surgery and early diagnosis.
    Pancreatic Cancer UK
    2023 - 2024
     
  • ECMC QQR 2023-2028
    Cancer Research UK
    2023 - 2024